Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713997 | 0.89 | CYP1A2 (0.57) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL16416490 | 0.86 | CYP1A2 (0.52) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL11063029 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL2783116 | 0.82 | CYP2C9 (0.54) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL17838295 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL25815772 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL21408377 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL20515037 | 0.77 | CYP1A2 (0.47) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL11199134 | 0.77 | CYP1A2 (0.47) | CYP1A2CYP2C19PKMKDM4EKMT2A | |
| SCHEMBL5041467 | 0.76 | CYP1A2 (0.38) | CYP1A2CYP2C19PKMKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-114867530-B | MCL1 inhibitors | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210171543-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021096860-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3793565-A1 | MCL-1 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112118845-A | MCL-1 inhibitors | 吉利德科学公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-20210171543-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | CYP1A2 4119/4885CYP2C19 4557/4885PKM 2949/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-12202842-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | CYP1A2 4052/4885CYP2C19 4496/4885PKM 2983/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | CYP1A2 4119/4885CYP2C19 4557/4885PKM 2949/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | CYP1A2 4119/4885CYP2C19 4557/4885PKM 2949/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP2C19 4851/4885PKM 2924/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | CYP1A2 4119/4885CYP2C19 4557/4885PKM 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.